The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: DCAF11 (DDB1- and CUL4-associated factor 11)

Gene Identity Verification

DCAF11 (gene symbol: DCAF11, UniProt accession: Q8TEB1) is also known as WDR23 (WD repeat-containing protein 23), consistent with the UniProt annotation provided (lo2017wdr23regulatesnrf2 pages 1-2, lo2017wdr23regulatesnrf2 pages 2-4). This protein functions as a substrate receptor within the Cullin-RING E3 ubiquitin ligase (CRL4) complex in human cells and contains WD40 repeat domains that facilitate protein-protein interactions (lo2017wdr23regulatesnrf2 pages 1-2, lo2017wdr23regulatesnrf2 pages 2-4). The gene matches the description of a DDB1- and CUL4-associated factor with WD40 domains as specified in the UniProt entry.

Molecular Function and Role as an E3 Ligase Substrate Receptor

Core Molecular Mechanism

DCAF11 functions as a substrate receptor subunit within the multicomponent CRL4 E3 ubiquitin ligase complex, which is composed of CUL4A or CUL4B (cullin scaffold proteins), RBX1 (RING-box protein 1), DDB1 (DNA damage-binding protein 1 adaptor), and DCAF11 as the substrate recognition module (chen2017crl4bdcaf11e3ligase pages 1-2, chen2017crl4bdcaf11e3ligase pages 2-4). The CRL4^DCAF11 complex catalyzes the transfer of ubiquitin from E2 ubiquitin-conjugating enzymes to specific protein substrates recognized by DCAF11, thereby marking these substrates for proteasomal degradation or functional modification (chen2017crl4bdcaf11e3ligase pages 1-2, lo2017wdr23regulatesnrf2 pages 1-2, lo2017wdr23regulatesnrf2 pages 2-4).

Structurally, DCAF11 contains seven WD40 repeats, which form a β-propeller structure that mediates substrate recognition and binding (lo2017wdr23regulatesnrf2 pages 2-4). This architecture allows DCAF11 to serve as a versatile adaptor that links the core CRL4 machinery to diverse cellular substrates depending on post-translational modifications and cellular context.

Substrate Specificity and Recognition Motifs

DCAF11 recognizes multiple substrates through distinct binding motifs and phosphorylation-dependent mechanisms. A comprehensive summary of known DCAF11 substrates is provided below:

Table: This table summarizes the main proteins reported to be regulated by the human DCAF11/WDR23-containing CRL4 ubiquitin ligase system, including recognition features, ubiquitination outcome, and biological role. It is useful for distinguishing direct proteolytic substrates from indirect or non-proteolytic regulatory effects.

The primary characterized substrates include:

NRF2 (Nuclear factor E2-related factor 2): DCAF11 binds to the DIDLID sequence within the Neh2 domain of NRF2, a motif that is distinct from the KEAP1-binding DLG and ETGE motifs (lo2017wdr23regulatesnrf2 pages 1-2, lo2017wdr23regulatesnrf2 pages 2-4). This enables DCAF11 to regulate NRF2 protein stability independently of the canonical KEAP1-CUL3 pathway. The WDR23-DDB1-CUL4 axis promotes NRF2 ubiquitination and degradation, thereby negatively regulating the expression of antioxidant response element (ARE)-containing genes involved in cellular cytoprotection and oxidative stress response (lo2017wdr23regulatesnrf2 pages 1-2, lo2017wdr23regulatesnrf2 pages 2-4). Recent studies demonstrate that loss of WDR23 stabilizes NRF2 and enhances expression of NRF2 target genes in both mouse hippocampus and human cell models (duangjan2024hepaticwdr23proteostasis pages 1-3, liu2024wdr23mediatesnrf2 pages 1-6).

p21Cip1 (CDKN1A): In osteosarcoma cells, the CRL4B^DCAF11 complex specifically ubiquitinates the cyclin-dependent kinase inhibitor p21Cip1 at lysine residues K16, K154, K161, and K163, but not at K75 or K141 (chen2017crl4bdcaf11e3ligase pages 1-2, chen2017crl4bdcaf11e3ligase pages 2-4). This targeted degradation of p21 promotes S-phase progression and cell cycle advancement. Knockdown of CUL4B, DDB1, or DCAF11 attenuates p21 ubiquitination, leading to S-phase arrest and decreased proliferation in osteosarcoma cells (chen2017crl4bdcaf11e3ligase pages 1-2, chen2017crl4bdcaf11e3ligase pages 2-4).

SLBP (Stem-loop binding protein): DCAF11 mediates the degradation of SLBP at the end of S phase through a phosphorylation-dependent mechanism (djakbarova2016ddb1andcul4 pages 1-4, djakbarova2016ddb1andcul4 pages 4-8). SLBP, which binds to the 3' stem-loop structure of replication-dependent histone mRNAs, is phosphorylated at Thr61 by cyclin A/Cdk1 and subsequently at Thr60 by CK2 (djakbarova2016ddb1andcul4 pages 4-8). The doubly phosphorylated SLBP is then recognized by DCAF11, ubiquitinated by the CRL4-DCAF11 complex, and degraded by the proteasome (djakbarova2016ddb1andcul4 pages 1-4, djakbarova2016ddb1andcul4 pages 4-8). This degradation is essential for terminating bulk histone synthesis at the S/G2 boundary and maintaining genomic stability.

GEN-1 (Holliday junction resolvase): DCAF11/WDR23 has been identified as a regulator of GEN-1, an evolutionarily conserved enzyme involved in DNA double-strand break repair (spatola2019nuclearandcytoplasmic pages 1-2). Studies in C. elegans and mammalian systems demonstrate that nuclear and cytoplasmic isoforms of WDR23 differentially affect GEN-1 activity and DNA repair processes, suggesting context-dependent regulatory mechanisms (spatola2019nuclearandcytoplasmic pages 1-2).

Insulin-Degrading Enzyme (IDE): Recent work establishes that hepatic WDR23 regulates insulin homeostasis indirectly through control of IDE expression (duangjan2024hepaticwdr23proteostasis pages 1-3). Loss of WDR23 leads to NRF2 stabilization, which in turn drives transcriptional upregulation of IDE, resulting in increased insulin degradation, reduced circulating insulin levels, and impaired insulin responses in mouse models (duangjan2024hepaticwdr23proteostasis pages 1-3). Genetic variation in WDR23 was significantly associated with altered hemoglobin A1C (HbA1c) levels in a large human aging cohort, supporting WDR23 as a molecular determinant of metabolic health (duangjan2024hepaticwdr23proteostasis pages 1-3).

Influenza A PB2 protein: DCAF11, along with DCAF12L1, mediates non-proteolytic K29-linked ubiquitination of the influenza A virus PB2 replication protein (karim2020nonproteolytick29linkedubiquitination pages 1-2). This atypical ubiquitin modification does not target PB2 for degradation but rather promotes optimal viral replication and virion production, representing a proviral function of the CRL4-DCAF11 complex (karim2020nonproteolytick29linkedubiquitination pages 1-2).

Subcellular Localization

DCAF11/WDR23 is expressed as two major protein isoforms with distinct subcellular distributions (lo2017wdr23regulatesnrf2 pages 2-4, spatola2019nuclearandcytoplasmic pages 1-2):

• Isoform 1 (UniProtKB Q8TEB1-2; 546 amino acids, 61.7 kDa) localizes primarily to the cytoplasm and regulates cytoplasmic substrates including NRF2 (lo2017wdr23regulatesnrf2 pages 2-4).

• Isoform 2 (UniProtKB Q8TEB1-1; 520 amino acids, 58.8 kDa) is enriched in the nucleus but can also be found in the cytoplasm when overexpressed (lo2017wdr23regulatesnrf2 pages 2-4). This nuclear isoform is positioned to regulate nuclear substrates such as SLBP and GEN-1 (spatola2019nuclearandcytoplasmic pages 1-2).

The dual subcellular localization of DCAF11 isoforms enables coordinate regulation of substrates in both the cytoplasm and nucleus, expanding the functional repertoire of the CRL4^DCAF11 E3 ligase system. Importantly, the subcellular distribution of WDR23 does not change in response to oxidative stress, suggesting constitutive localization patterns (lo2017wdr23regulatesnrf2 pages 2-4). This contrasts with KEAP1, which is predominantly cytoplasmic, highlighting how DCAF11 can regulate NRF2 in compartments not accessible to KEAP1-CUL3 (lo2017wdr23regulatesnrf2 pages 2-4).

Biological Processes and Signaling Pathways

DCAF11 participates in multiple critical cellular processes through its substrate-specific activities:

1. Oxidative Stress Response and Cytoprotection

DCAF11 is a key negative regulator of the NRF2-mediated oxidative stress response pathway, operating independently of the canonical KEAP1-CUL3 system (lo2017wdr23regulatesnrf2 pages 1-2, lo2017wdr23regulatesnrf2 pages 2-4). By promoting NRF2 degradation, DCAF11 controls the expression of antioxidant enzymes (e.g., GSR, GSTA1, HO-1, GSTM1), drug-metabolizing enzymes (e.g., CYP3A4, CYP1A1), and other cytoprotective factors (lo2017wdr23regulatesnrf2 pages 1-2, lo2017wdr23regulatesnrf2 pages 2-4, liu2024wdr23mediatesnrf2 pages 1-6). Loss of WDR23 in mice leads to NRF2 stabilization, increased expression of antioxidant defense proteins, and enhanced oxidative stress resistance (liu2024wdr23mediatesnrf2 pages 1-6). This regulatory axis is particularly important in the nervous system, where WDR23-mediated NRF2 proteostasis influences hippocampal cytoprotective capacity and age-related behavioral changes (liu2024wdr23mediatesnrf2 pages 1-6).

Notably, transcription factor TFEB represses DCAF11 expression at both the protein and mRNA levels, leading to NRF2 stabilization and activation even under non-oxidative stress conditions (park2019tfebactivatesnrf2 pages 1-2). This establishes a TFEB-DCAF11-NRF2 regulatory axis that coordinates autophagy-lysosomal and antioxidant response pathways (park2019tfebactivatesnrf2 pages 1-2).

2. Cell Cycle Progression

DCAF11 plays essential roles in controlling cell cycle transitions, particularly at the G1/S and S/G2 boundaries:

• S-phase progression: By degrading p21Cip1, DCAF11 relieves inhibition of cyclin-CDK complexes, thereby promoting DNA replication and S-phase progression (chen2017crl4bdcaf11e3ligase pages 1-2, chen2017crl4bdcaf11e3ligase pages 2-4). Dysregulation of this pathway can contribute to uncontrolled proliferation in osteosarcoma and potentially other cancers.

• S/G2 transition: DCAF11-mediated degradation of SLBP at the end of S phase is critical for terminating histone biosynthesis (djakbarova2016ddb1andcul4 pages 1-4, djakbarova2016ddb1andcul4 pages 4-8). This ensures proper coupling of histone production with DNA replication and prevents deleterious imbalances between DNA and histone levels that could compromise genomic stability (djakbarova2016ddb1andcul4 pages 4-8). Ectopic expression of S/G2-stable SLBP mutants (Thr61/Ala) is significantly more toxic to cells compared to wild-type SLBP, underscoring the importance of DCAF11-mediated SLBP degradation for cell viability (djakbarova2016ddb1andcul4 pages 4-8).

3. DNA Damage Repair

Through regulation of GEN-1, a Holliday junction resolvase, DCAF11 influences the cellular capacity for DNA double-strand break repair (spatola2019nuclearandcytoplasmic pages 1-2). The nuclear WDR-23B isoform appears to negatively regulate GEN-1 activity, most likely through promoting protein turnover, while the cytoplasmic WDR-23A isoform may perform proteasome-independent regulatory functions (spatola2019nuclearandcytoplasmic pages 1-2). This differential regulation by spatially distinct DCAF11 isoforms ensures appropriate coordination of DNA repair processes.

4. Metabolic Regulation and Insulin Homeostasis

Recent work has established a hepatic WDR23-NRF2-IDE regulatory axis that controls insulin clearance and metabolic balance (duangjan2024hepaticwdr23proteostasis pages 1-3). In Wdr23 knockout mice, loss of WDR23 leads to:
- Increased IDE expression through NRF2-mediated transcriptional activation
- Reduced circulating insulin levels
- Impaired insulin signaling and insulin sensitivity (particularly in male mice)
- Dysregulated phosphorylation of insulin signaling proteins (IRS-1, AKT2, MAPK, FoxO, mTOR) (duangjan2024hepaticwdr23proteostasis pages 1-3)

Importantly, genetic variation in WDR23 was significantly associated with altered HbA1c levels in a large human cohort, supporting WDR23 as a molecular determinant of metabolic health and a potential biomarker for diabetes risk (duangjan2024hepaticwdr23proteostasis pages 1-3).

5. Viral Infection

DCAF11 contributes to influenza A virus replication through non-proteolytic K29-linked ubiquitination of the viral PB2 replication protein (karim2020nonproteolytick29linkedubiquitination pages 1-2). This atypical ubiquitin modification promotes optimal viral cycle progression and maximal virion production without targeting PB2 for degradation, representing a proviral host-pathogen interaction (karim2020nonproteolytick29linkedubiquitination pages 1-2).

Recent Developments and Applications in Drug Discovery (2023–2024)

Recent 2023–2024 chemical biology studies position DCAF11/WDR23 as an increasingly actionable CRL4 substrate receptor for targeted protein degradation, extending the E3-ligase toolbox beyond CRBN and VHL. Drug-like covalent DCAF11 ligands and DCAF11-recruiting degraders were reported to drive degradation of proteins such as BRD4 and to show antitumor activity in cells and, for some compounds, in mouse xenograft models, supporting expert views that DCAF11 is now a bona fide TPD platform rather than merely a poorly characterized adaptor. URLs: https://doi.org/10.1038/s41467-023-43657-6 ; https://doi.org/10.1371/journal.pbio.3002550 ; https://doi.org/10.1158/1535-7163.MCT-24-0219 (xue2023discoveryofa pages 1-2, wang2024alkenyloxindoleis pages 1-2, parker2024discoveryofmonovalent pages 1-2)

Mechanistically, these advances build on foundational evidence that DCAF11/WDR23 is a DDB1-CUL4-associated substrate receptor that can recognize and regulate specific targets, most notably NRF2/NFE2L2, independently of the canonical KEAP1-CUL3 pathway. This has made DCAF11 especially interesting to experts because it links degrader chemistry directly to a biologically validated stress-response node with implications for cancer resistance, redox biology, and cytoprotection. URLs: https://doi.org/10.1371/journal.pgen.1006762 ; https://doi.org/10.1038/s41598-019-50877-8 (lo2017wdr23regulatesnrf2 pages 1-2, park2019tfebactivatesnrf2 pages 1-2, lo2017wdr23regulatesnrf2 pages 2-4)

Authoritative 2024 work further strengthens the view that WDR23 is not only relevant to degradation technology but also to physiology: loss of WDR23 increased IDE expression through NRF2-dependent transcription, reduced circulating insulin, altered insulin signaling, and was associated with altered HbA1c in a large human aging cohort, highlighting a plausible metabolic-disease connection. In parallel, 2024 nervous-system studies reinforced that WDR23-mediated NRF2 proteostasis shapes hippocampal antioxidant programs, underscoring broader tissue-specific roles in oxidative-stress adaptation. URLs: https://doi.org/10.1007/s11357-024-01196-y ; https://doi.org/10.1016/j.mad.2024.111914 (duangjan2024hepaticwdr23proteostasis pages 1-3, liu2024wdr23mediatesnrf2 pages 1-6)

Overall, the current expert consensus from these studies is that DCAF11/WDR23 should be viewed as a multifunctional CRL4 substrate receptor at the intersection of proteostasis, oxidative-stress control, cell-state regulation, and emerging therapeutic modality design. The major open question is no longer whether DCAF11 is druggable, but how broadly and selectively its endogenous substrate-recognition biology can be harnessed across cancer, neurodegeneration, and metabolic disease contexts. (xue2023discoveryofa pages 1-2, duangjan2024hepaticwdr23proteostasis pages 1-3, liu2024wdr23mediatesnrf2 pages 1-6, wang2024alkenyloxindoleis pages 1-2, parker2024discoveryofmonovalent pages 1-2)

Blockquote: This blockquote summarizes recent expert-relevant developments on DCAF11/WDR23 across targeted protein degradation, oxidative-stress regulation, and metabolic disease links. It is useful as a concise synthesis of why DCAF11 has become a notable E3 ligase substrate receptor in current research.

A major recent development is the recognition of DCAF11 as a druggable E3 ligase substrate receptor for targeted protein degradation (TPD) strategies. Several 2023–2024 studies have established DCAF11 as a viable alternative to the commonly used CRBN and VHL E3 ligases in proteolysis-targeting chimera (PROTAC) design:

Covalent DCAF11 Ligands: Xue et al. (2023) discovered that arylidene-indolinone compounds, which contain tempered α,β-unsaturated electrophiles, covalently bind to specific cysteine residues in DCAF11, including the highly conserved C460 (xue2023discoveryofa pages 1-2). These drug-like compounds recruit the CRL4^DCAF11 E3 ligase to degrade target proteins conjugated to them, enabling TPD applications (xue2023discoveryofa pages 1-2).

DCAF11-recruiting PROTACs: Wang et al. (2024) demonstrated that alkenyl oxindole-based heterobifunctional molecules recruit the CRL4^DCAF11 complex to induce ubiquitin-proteasome-mediated degradation of BRD4 and other targets (wang2024alkenyloxindoleis pages 1-2). Using pooled CRISPR interference screening, they confirmed that JQ1-alkenyl oxindole conjugates require DCAF11 for substrate degradation activity (wang2024alkenyloxindoleis pages 1-2). The lead compound HL435 showed promising antitumor activity both in vitro and in mouse xenograft models (wang2024alkenyloxindoleis pages 1-2).

Monovalent DCAF11 Degraders: Parker et al. (2024) identified monovalent "direct" degraders of BRD4 that bind to the target protein and induce its degradation through endogenous recruitment of DCAF11 (parker2024discoveryofmonovalent pages 1-2). The lead compound PLX-3618 demonstrated selective BRD4 degradation, potent antitumor activity in vivo, and formation of a BRD4:PLX-3618:DCAF11 ternary complex. Mutational studies provided mechanistic insights into DCAF11-mediated degradation, and CRISPR screens confirmed that DCAF11 is required for PLX-3618 activity (parker2024discoveryofmonovalent pages 1-2).

These advances position DCAF11 as an increasingly actionable E3 ligase for TPD modalities, expanding the toolbox beyond CRBN and VHL. This is particularly important for overcoming acquired resistance to CRBN-based degraders, as DCAF11-based PROTACs retain activity in CRBN-resistant cell lines (wang2024alkenyloxindoleis pages 1-2, parker2024discoveryofmonovalent pages 1-2).

Cancer and Disease Implications

DCAF11 has been implicated in tumorigenesis with context-dependent roles:

• Potential tumor suppressor: DCAF11 has been suggested as a potential tumor suppressor in some contexts, possibly through its role in regulating cell cycle checkpoints and DNA damage repair (chen2017crl4bdcaf11e3ligase pages 1-2, chen2017crl4bdcaf11e3ligase pages 2-4).

• Oncogenic potential: Overexpression of CUL4B and DCAF11 in osteosarcoma cells promotes p21 degradation and uncontrolled proliferation, suggesting oncogenic functions in specific cancer types (chen2017crl4bdcaf11e3ligase pages 1-2, chen2017crl4bdcaf11e3ligase pages 2-4).

• Chemo-resistance: Dysregulation of NRF2 due to loss of KEAP1 is a hallmark of several chemo- and radiation-resistant cancers (lo2017wdr23regulatesnrf2 pages 1-2, lo2017wdr23regulatesnrf2 pages 2-4). The identification of WDR23 as an alternative NRF2 regulator suggests that modulating WDR23 activity could provide therapeutic benefit in KEAP1-mutant cancers where the canonical regulatory pathway is impaired (lo2017wdr23regulatesnrf2 pages 1-2, lo2017wdr23regulatesnrf2 pages 2-4).

• Metabolic disease: The association of WDR23 genetic variation with altered HbA1c levels in human populations supports its relevance to type 2 diabetes risk and metabolic syndrome (duangjan2024hepaticwdr23proteostasis pages 1-3).

Evolutionary Conservation and Model Organism Studies

The WDR23/DCAF11 regulatory system is evolutionarily conserved from C. elegans to humans (lo2017wdr23regulatesnrf2 pages 2-4, spatola2019nuclearandcytoplasmic pages 1-2). In C. elegans, WDR-23 regulates SKN-1 (the worm ortholog of mammalian NRF2) through the CUL-4-DDB-1 E3 ligase complex, controlling oxidative stress responses and lifespan (lo2017wdr23regulatesnrf2 pages 2-4, spatola2019nuclearandcytoplasmic pages 1-2). Notably, C. elegans lacks a KEAP1 homolog, suggesting that the WDR23-mediated regulatory pathway represents an ancient mechanism of cytoprotective transcription factor control that predates the evolution of KEAP1 (lo2017wdr23regulatesnrf2 pages 2-4).

The high degree of conservation between worm WDR-23 and human DCAF11/WDR23, particularly in the C-terminal WD40 repeat domain, supports the use of C. elegans as a model system to elucidate conserved regulatory mechanisms relevant to human physiology and disease (lo2017wdr23regulatesnrf2 pages 2-4).

Conclusions

DCAF11 (WDR23) is a multifunctional substrate receptor within the CRL4 E3 ubiquitin ligase complex that regulates diverse cellular processes including oxidative stress response, cell cycle progression, DNA damage repair, metabolic homeostasis, and host-pathogen interactions. Its ability to recognize multiple substrates through distinct binding motifs and phosphorylation-dependent mechanisms, combined with its dual nuclear-cytoplasmic localization through alternative isoforms, enables DCAF11 to coordinate proteostasis across cellular compartments.

The identification of DCAF11 as a KEAP1-independent regulator of NRF2 has significant implications for understanding oxidative stress biology and for developing therapeutic strategies in cancers with KEAP1 mutations. Recent advances establishing DCAF11 as a druggable E3 ligase for targeted protein degradation further highlight its potential as a therapeutic target and tool for chemical biology.

Future research directions include further defining the complete substrate repertoire of DCAF11, elucidating the structural basis of substrate recognition, characterizing tissue-specific functions, and developing selective DCAF11 modulators for therapeutic applications in cancer, neurodegeneration, and metabolic disease.

References

1. (lo2017wdr23regulatesnrf2 pages 1-2): Jacqueline Y. Lo, Brett N. Spatola, and Sean P. Curran. Wdr23 regulates nrf2 independently of keap1. PLOS Genetics, 13:e1006762, Apr 2017. URL: https://doi.org/10.1371/journal.pgen.1006762, doi:10.1371/journal.pgen.1006762. This article has 133 citations and is from a domain leading peer-reviewed journal.

2. (lo2017wdr23regulatesnrf2 pages 2-4): Jacqueline Y. Lo, Brett N. Spatola, and Sean P. Curran. Wdr23 regulates nrf2 independently of keap1. PLOS Genetics, 13:e1006762, Apr 2017. URL: https://doi.org/10.1371/journal.pgen.1006762, doi:10.1371/journal.pgen.1006762. This article has 133 citations and is from a domain leading peer-reviewed journal.

3. (chen2017crl4bdcaf11e3ligase pages 1-2): Zhi Chen, Kun Wang, Cang-long Hou, Kaibiao Jiang, Bin Chen, Jianwei Chen, Lifeng Lao, Lie Qian, Guibin Zhong, Zude Liu, Caiguo Zhang, and Hongxing Shen. Crl4bdcaf11 e3 ligase targets p21 for degradation to control cell cycle progression in human osteosarcoma cells. Scientific Reports, Apr 2017. URL: https://doi.org/10.1038/s41598-017-01344-9, doi:10.1038/s41598-017-01344-9. This article has 57 citations and is from a peer-reviewed journal.

4. (chen2017crl4bdcaf11e3ligase pages 2-4): Zhi Chen, Kun Wang, Cang-long Hou, Kaibiao Jiang, Bin Chen, Jianwei Chen, Lifeng Lao, Lie Qian, Guibin Zhong, Zude Liu, Caiguo Zhang, and Hongxing Shen. Crl4bdcaf11 e3 ligase targets p21 for degradation to control cell cycle progression in human osteosarcoma cells. Scientific Reports, Apr 2017. URL: https://doi.org/10.1038/s41598-017-01344-9, doi:10.1038/s41598-017-01344-9. This article has 57 citations and is from a peer-reviewed journal.

5. (park2019tfebactivatesnrf2 pages 1-2): Jee-Yun Park, Sunhyo Kim, Hee Young Sohn, Young Ho Koh, and Chulman Jo. Tfeb activates nrf2 by repressing its e3 ubiquitin ligase dcaf11 and promoting phosphorylation of p62. Scientific Reports, Oct 2019. URL: https://doi.org/10.1038/s41598-019-50877-8, doi:10.1038/s41598-019-50877-8. This article has 51 citations and is from a peer-reviewed journal.

6. (djakbarova2016ddb1andcul4 pages 1-4): Umidahan Djakbarova, William F. Marzluff, and M. Murat Köseoğlu. Ddb1 and cul4 associated factor 11 (dcaf11) mediates degradation of stem-loop binding protein at the end of s phase. Cell Cycle, 15:1986-1996, Jul 2016. URL: https://doi.org/10.1080/15384101.2016.1191708, doi:10.1080/15384101.2016.1191708. This article has 30 citations and is from a peer-reviewed journal.

7. (djakbarova2016ddb1andcul4 pages 4-8): Umidahan Djakbarova, William F. Marzluff, and M. Murat Köseoğlu. Ddb1 and cul4 associated factor 11 (dcaf11) mediates degradation of stem-loop binding protein at the end of s phase. Cell Cycle, 15:1986-1996, Jul 2016. URL: https://doi.org/10.1080/15384101.2016.1191708, doi:10.1080/15384101.2016.1191708. This article has 30 citations and is from a peer-reviewed journal.

8. (spatola2019nuclearandcytoplasmic pages 1-2): Brett N. Spatola, Jacqueline Y. Lo, Bin Wang, and Sean P. Curran. Nuclear and cytoplasmic wdr-23 isoforms mediate differential effects on gen-1 and skn-1 substrates. Scientific Reports, Aug 2019. URL: https://doi.org/10.1038/s41598-019-48286-y, doi:10.1038/s41598-019-48286-y. This article has 24 citations and is from a peer-reviewed journal.

9. (duangjan2024hepaticwdr23proteostasis pages 1-3): Chatrawee Duangjan, Thalida Em Arpawong, Brett N. Spatola, and Sean P. Curran. Hepatic wdr23 proteostasis mediates insulin homeostasis by regulating insulin-degrading enzyme capacity. GeroScience, 46:4461-4478, May 2024. URL: https://doi.org/10.1007/s11357-024-01196-y, doi:10.1007/s11357-024-01196-y. This article has 5 citations and is from a peer-reviewed journal.

10. (karim2020nonproteolytick29linkedubiquitination pages 1-2): Marwah Karim, Elise Biquand, Marion Declercq, Yves Jacob, Sylvie van der Werf, and Caroline Demeret. Nonproteolytic k29-linked ubiquitination of the pb2 replication protein of influenza a viruses by proviral cullin 4-based e3 ligases. Apr 2020. URL: https://doi.org/10.1128/mbio.00305-20, doi:10.1128/mbio.00305-20. This article has 44 citations and is from a domain leading peer-reviewed journal.

11. (liu2024wdr23mediatesnrf2 pages 1-6): Jiahui Liu, Chatrawee Duangjan, Ronald W. Irwin, and Sean P. Curran. Wdr23 mediates nrf2 proteostasis and cytoprotective capacity in the hippocampus. Mechanisms of Ageing and Development, 218:111914, Apr 2024. URL: https://doi.org/10.1016/j.mad.2024.111914, doi:10.1016/j.mad.2024.111914. This article has 6 citations and is from a peer-reviewed journal.

12. (xue2023discoveryofa pages 1-2): Gang Xue, Jianing Xie, Matthias Hinterndorfer, Marko Cigler, Lara Dötsch, Hana Imrichová, Philipp Lampe, Xiufen Cheng, Soheila Rezaei Adariani, Georg E. Winter, and Herbert Waldmann. Discovery of a drug-like, natural product-inspired dcaf11 ligand chemotype. Nature Communications, Nov 2023. URL: https://doi.org/10.1038/s41467-023-43657-6, doi:10.1038/s41467-023-43657-6. This article has 62 citations and is from a highest quality peer-reviewed journal.

13. (wang2024alkenyloxindoleis pages 1-2): Ying Wang, Tianzi Wei, Man Zhao, Aima Huang, Fan Sun, Lu Chen, Risheng Lin, Yubao Xie, Ming Zhang, Shiyu Xu, Zhihui Sun, Liang Hong, Rui Wang, Ruilin Tian, and Guofeng Li. Alkenyl oxindole is a novel protac moiety that recruits the crl4dcaf11 e3 ubiquitin ligase complex for targeted protein degradation. PLOS Biology, 22:e3002550, May 2024. URL: https://doi.org/10.1371/journal.pbio.3002550, doi:10.1371/journal.pbio.3002550. This article has 22 citations and is from a highest quality peer-reviewed journal.

14. (parker2024discoveryofmonovalent pages 1-2): Gregory S. Parker, Julia I. Toth, Sarah Fish, Gabrielle Blanco, Taylor Kampert, Xiaoming Li, Linette Yang, Craig R. Stumpf, Kenneth Steadman, Aleksandar Jamborcic, Stephen Chien, Elizabeth Daniele, Alejandro Dearie, Geoffray Leriche, Simon Bailey, and Peggy A. Thompson. Discovery of monovalent direct degraders of brd4 that act via the recruitment of dcaf11. Molecular Cancer Therapeutics, 23:1446-1458, Jun 2024. URL: https://doi.org/10.1158/1535-7163.mct-24-0219, doi:10.1158/1535-7163.mct-24-0219. This article has 19 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01

Citations

1. spatola2019nuclearandcytoplasmic pages 1-2
2. xue2023discoveryofa pages 1-2
3. wang2024alkenyloxindoleis pages 1-2
4. parker2024discoveryofmonovalent pages 1-2
5. https://doi.org/10.1038/s41467-023-43657-6
6. https://doi.org/10.1371/journal.pbio.3002550
7. https://doi.org/10.1158/1535-7163.MCT-24-0219
8. https://doi.org/10.1371/journal.pgen.1006762
9. https://doi.org/10.1038/s41598-019-50877-8
10. https://doi.org/10.1007/s11357-024-01196-y
11. https://doi.org/10.1016/j.mad.2024.111914
12. https://doi.org/10.1371/journal.pgen.1006762,
13. https://doi.org/10.1038/s41598-017-01344-9,
14. https://doi.org/10.1038/s41598-019-50877-8,
15. https://doi.org/10.1080/15384101.2016.1191708,
16. https://doi.org/10.1038/s41598-019-48286-y,
17. https://doi.org/10.1007/s11357-024-01196-y,
18. https://doi.org/10.1128/mbio.00305-20,
19. https://doi.org/10.1016/j.mad.2024.111914,
20. https://doi.org/10.1038/s41467-023-43657-6,
21. https://doi.org/10.1371/journal.pbio.3002550,
22. https://doi.org/10.1158/1535-7163.mct-24-0219,